Farallon Capital Management LLC Decreases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Farallon Capital Management LLC trimmed its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,123,151 shares of the medical research company’s stock after selling 47,932 shares during the quarter. IQVIA accounts for 3.1% of Farallon Capital Management LLC’s holdings, making the stock its 7th largest holding. Farallon Capital Management LLC’s holdings in IQVIA were worth $613,730,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in IQV. Principal Financial Group Inc. grew its position in IQVIA by 0.8% in the third quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company’s stock valued at $49,532,000 after acquiring an additional 1,750 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after buying an additional 583,396 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after acquiring an additional 56 shares in the last quarter. Czech National Bank increased its holdings in IQVIA by 6.0% in the 4th quarter. Czech National Bank now owns 37,386 shares of the medical research company’s stock worth $7,347,000 after purchasing an additional 2,107 shares in the last quarter. Finally, Claro Advisors LLC bought a new stake in shares of IQVIA during the fourth quarter worth about $281,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Hsbc Global Res lowered shares of IQVIA from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. HSBC lowered IQVIA from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. UBS Group lowered their target price on IQVIA from $255.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday. Barclays reduced their price target on shares of IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, Mizuho decreased their target price on shares of IQVIA from $242.00 to $210.00 and set an “outperform” rating for the company in a research report on Wednesday, April 9th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $231.71.

IQVIA Stock Up 0.1 %

IQV stock opened at $153.39 on Friday. The stock has a 50-day simple moving average of $164.60 and a two-hundred day simple moving average of $189.07. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The firm has a market capitalization of $27.04 billion, a PE ratio of 20.45, a PEG ratio of 1.99 and a beta of 1.34.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to analysts’ expectations of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.54 EPS. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.